It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2021.11.01.21265773;](https://doi.org/10.1101/2021.11.01.21265773) this version posted November 2, 2021. The copyright holder for this preprint

¹**CELL-FREE TUMOR DNA DOMINANT CLONE ALLELE FREQUENCY (DCAF) IS** ²**ASSOCIATED WITH POOR OUTCOMES IN ADVANCED BILIARY CANCERS TREATED** ³**WITH PLATINUM-BASED CHEMOTHERAPY**

⁴**Running head: CELL-FREE TUMOR DNA IN ADVANCED BILIARY CANCERS**

5 Pedro Luiz Serrano Uson Junior^{1, 10}, Umair Majeed², Jun Yin⁹, Gehan Botrus¹, Mohamad 6 Bassam Sonbol¹, Daniel H. Ahn¹, Jason S. Starr², Jeremy C Jones², Hani Babiker², Samantha 7 R Inabinett², Natasha Wylie², Ashton WR Boyle², Tanios S. Bekaii-Saab¹, Gregory J Gores³, 8 Rory Smoot⁴, Michael Barrett⁵, Bolni Nagalo^{1, 11}, Nathalie Meurice^{1,5}, Natalie Elliott¹, Joachim 9 Petit¹, Yumei Zhou¹, Mansi Arora¹, Chelsae Dumbauld¹, Oumar Barro¹, Alexander Baker¹, 10 James Bogenberger¹, Kenneth Buetow⁶, Aaron Mansfield⁴, Kabir Mody^{2*}, Mitesh J. Borad^{1, 5, 7,8}*

- 11 1: Division of Hematology & Oncology, Department of Medicine, Mayo Clinic, Scottsdale, AZ,
- 12 USA
- ¹³2: Division of Hematology & Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL,
- 14 USA
- ¹⁵3: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Rochester,
- 16 MN, USA
- 17 4: Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
- 18 5: Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA
- ¹⁹6: Arizona State University, Tempe, AZ, USA
- 20 7: Department of Molecular Medicine, Rochester, MN, USA
- 21 8: Mayo Clinic Cancer Center, Phoenix, AZ, USA
- 22 9: Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA
- ²³10: Hospital Israelita Albert Einstein, São Paulo, Brazil
- 24 11: Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
- ²⁵*Equal contribution

26

- 27 Corresponding Author:
- 28 Mitesh J. Borad, M.D.
- ²⁹Email: Borad.Mitesh@Mayo.edu
- 30 Address: Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ
-

³²**ACKNOWLEDGEMENTS**

33 The Mayo Clinic Hepatobiliary SPORE (P50CA 210964) funded the statistical analysis for this
34 project. This work was supported by the National Institute of Health (NIH) through a DP2 Award 34 project. This work was supported by the National Institute of Health (NIH) through a DP2 Award
35 CA195764 (to MJB); National Cancer Institute (NCI) K12 award CA090628 (to MJB), K01 award 35 CA195764 (to MJB); National Cancer Institute (NCI) K12 award CA090628 (to MJB), K01 award
36 CA234324 (to BN), SPORE Project Award 5P50CA210964-03 (to GJG and MJB), SPORE ³⁶CA234324 (to BN), SPORE Project Award 5P50CA210964-03 **(**to GJG and MJB), SPORE 37 Supplement Award 3P50CA210964-02S1 (to OB), Mayo Clinic Center for Individualized
38 Medicine (CIM) Precision Cancer Therapeutics Program: and Mayo Clinic Cancer Center. The 38 Medicine (CIM) Precision Cancer Therapeutics Program; and Mayo Clinic Cancer Center. The
39 funders had no role in study design, data collection and analysis, decision to publish or 39 funders had no role in study design, data collection and analysis, decision to publish or
40 preparation of the manuscript. Its contents are solely the responsibility of the authors and do not 40 preparation of the manuscript. Its contents are solely the responsibility of the authors and do not 41 necessarily represent the official views of the NIH. necessarily represent the official views of the NIH.

- 42
- 43
-
-
-
- 46
-
-
- 49
-
-
-

⁵³**ABSTRACT**

⁵⁵**PURPOSE:** This investigation sough to evaluate the prognostic value of pre-treatment ctDNA in 56 metastatic biliary tract cancers (BTC) treated with platinum based first-line chemotherapy
57 treatment. 57 treatment.
58

⁵⁹**METHODS:** We performed a retrospective analysis of 67 patients who underwent ctDNA testing 60 before platinum-based chemotherapy for first-line treatment for metastatic BTC. For analysis we
61 considered the detected gene with highest variant allele frequency (VAF) as the dominant clone 61 considered the detected gene with highest variant allele frequency (VAF) as the dominant clone
62 allele frequency (DCAF). Results of ctDNA analysis were correlated with patients' 62 allele frequency (DCAF). Results of ctDNA analysis were correlated with patients'
63 demographics, progression-free-survival (PFS) and overall-survival (OS). 63 demographics, progression-free survival (PFS) and overall survival (OS).
64

65 ⁶⁵**RESULTS:** The median age of patients was 67 years (27-90). 54 (80.6%) of 67 patients 66 evaluated had intrahepatic cholangiocarcinoma; seven had extrahepatic cholangiocarcinoma
67 and six gallbladder cancers. 46 (68.6%) of the patients were treated with cisplatin plus 67 and six gallbladder cancers. 46 (68.6%) of the patients were treated with cisplatin plus
68 demcitabine, 16.4% of patients received gemcitabine and other platinum (carboplatin or 68 gemcitabine, 16.4% of patients received gemcitabine and other platinum (carboplatin or
69 oxaliplatin) combinations while 15% of patients were treated on a clinical trial with gemcitabine 69 oxaliplatin) combinations while 15% of patients were treated on a clinical trial with gemcitabine
60 and cisplatin plus additional agents (CX4945, PEGPH20 or nab-paclitaxel). TP53, KRAS, 70 and cisplatin plus additional agents (CX4945, PEGPH20 or nab-paclitaxel). TP53, KRAS,
71 FGFR2, ARID1A, STK11 and IDH1 were the genes with highest frequency as DCAF. Median 71 FGFR2, ARID1A, STK11 and IDH1 were the genes with highest frequency as DCAF. Median
72 DCAF was 3% (0-97%). DCAF >3% was associated with worse OS (median OS: 10.8 vs. 18.8 72 DCAF was 3% (0-97%). DCAF >3% was associated with worse OS (median OS: 10.8 vs. 18.8
73 months, p=0.032). Stratifying DCAF in quartiles, DCAF>10% was significantly related to worse 73 months, p=0.032). Stratifying DCAF in quartiles, DCAF>10% was significantly related to worse
74 PFS (median PFS: 3 months, p=0.014) and worse OS (median OS: 7.0 months, p=0.001). Each 74 PFS (median PFS: 3 months, p=0.014) and worse OS (median OS: 7.0 months, p=0.001). Each
75 1% increase in ctDNA was associated with a hazard ratio of 13.1 in OS when adjusting for 1% increase in ctDNA was associated with a hazard ratio of 13.1 in OS when adjusting for 76 subtypes, metastatic sites, size of largest tumor, age, sex, and CA19-9.
77

78 78 **CONCLUSION:** DCAF at diagnosis of advanced BTC can stratify patients who have worse
79 outcomes when treated with upfront platinum-based chemotherapy. Each increase in %ctDNA 79 outcomes when treated with upfront platinum-based chemotherapy. Each increase in %ctDNA
80 decrease survival probabilities. decrease survival probabilities.

⁸²**KEYWORDS:** Biliary tract cancers, cell-free tumor DNA, liquid biopsy, cholangiocarcinoma

⁸⁴**INTRODUCTION**

85

86 Biliary tract cancers (BTCs) include intrahepatic cholangiocarcinoma (IHC), gallbladder cancer
87 (GBC) and extrahepatic cholangiocarcinoma (EHC) and ampulla of Vater cancers (AVC) [1]. 87 (GBC) and extrahepatic cholangiocarcinoma (EHC) and ampulla of Vater cancers (AVC) [1].
88 BTC represents 3% of gastrointestinal malignancies with 11,980 cases expected to be 88 BTC represents 3% of gastrointestinal malignancies with 11,980 cases expected to be
89 diagnosed in 2021 [2, 3]. As BTC usually present at an advanced stage only 20% of these 89 diagnosed in 2021 [2, 3]. As BTC usually present at an advanced stage only 20% of these
90 tumors are considered resectable [4]. In patients with unresectable disease the 5-year overall 90 tumors are considered resectable [4]. In patients with unresectable disease the 5-year overall 91 survival is about 4% [5]. survival is about 4% [5].

92 The survival gain with first-line chemotherapy regimens in BTC is modest since most patients
93 develop progressive disease with a median overall survival (OS) of less than a year [6]. This 93 develop progressive disease with a median overall survival (OS) of less than a year [6]. This
94 has generated interest in using next-generation tumor genomic profiling (NGS) and liquid tumor 94 has generated interest in using next-generation tumor genomic profiling (NGS) and liquid tumor
95 biopsy on peripheral blood to look for targetable genetic alterations [7, 8]. ⁹⁵biopsy on peripheral blood to look for targetable genetic alterations [7, 8].

96 Circulating tumor DNA (ctDNA) has been shown to carry tumor-specific genetic or epigenetic
97 alterations including point mutations, copy number variations, chromosomal rearrangements, 97 alterations including point mutations, copy number variations, chromosomal rearrangements,
98 and DNA methylation. This ctDNA is released into the circulation after tumor cells undergo 98 and DNA methylation. This ctDNA is released into the circulation after tumor cells undergo
99 apoptosis or necrosis [9]. Evaluation of ctDNA can identify patient specific tumoral genetic 99 apoptosis or necrosis [9]. Evaluation of ctDNA can identify patient specific tumoral genetic
100 alterations while allowing for serial monitoring of tumor genomes in a non-invasive and accurate 100 alterations while allowing for serial monitoring of tumor genomes in a non-invasive and accurate
101 manner [8]. Therapeutically relevant alterations were seen in ctDNA in 55% of biliary tract 101 manner [8]. Therapeutically relevant alterations were seen in ctDNA in 55% of biliary tract
102 cancer patients [8]. Due to these findings the strategy is being used in the setting of advanced cancer patients [8]. Due to these findings the strategy is being used in the setting of advanced
103 disease for treatment selection [10]. Furthermore, it has also been used as an early marker of 103 disease for treatment selection [10]. Furthermore, it has also been used as an early marker of 104
104 response to treatment and to track mechanisms of acquired resistance [11]. response to treatment and to track mechanisms of acquired resistance [11].

105 In colon and breast cancer ctDNA has been used to predict response to treatment and 106 prognosis in the adjuvant and neoadjuvant setting respectively [12, 13]. One marker of interest
107 is variant allele frequency (VAF), which is the number of mutant molecules over total number of 107 is variant allele frequency (VAF), which is the number of mutant molecules over total number of
108 wild-type molecules at a specific location on the genome. Pairawan et al showed that VAF is a 108 wild-type molecules at a specific location on the genome. Pairawan et.al showed that VAF is a
109 surrogate marker of tumor burden and maximum VAF (VAFmax) correlated negatively with 109 surrogate marker of tumor burden and maximum VAF (VAFmax) correlated negatively with 110 prognosis and survival in metastatic cancer [14]. prognosis and survival in metastatic cancer [14].

111 In this study we hypothesized that the dominant clone allele frequency (DCAF) on ctDNA in
112 biliary tract cancer would be associated with overall survival (OS) and progression free survival biliary tract cancer would be associated with overall survival (OS) and progression free survival

113 (PFS) and can serve as a surrogate of disease volume and severity. In addition, we looked at
114 Frelationship of DCAF to treatment response with first-line platinum-based chemotherapy and 114 relationship of DCAF to treatment response with first-line platinum-based chemotherapy and 115 clinical demographics. clinical demographics.

¹¹⁶**MATERIALS AND METHODS**

¹¹⁷*Patients*

118

119 From July 2016 through June 2020, 67 patients with advanced BTC underwent ctDNA testing at
120 diagnosis using an available assay [Guardant Health, Inc. (Redwood City, CA)]. All the patients diagnosis using an available assay [Guardant Health, Inc. (Redwood City, CA)]. All the patients 121 received care at Mayo Clinic Cancer Center in Arizona and Florida. The analysis from this
122 cohort was reviewed and approved by the Mayo Clinic institutional review board. Clinical and 122 cohort was reviewed and approved by the Mayo Clinic institutional review board. Clinical and
123 demographic information of all patients are included in Table 1. 123 demographic information of all patients are included in Table 1.
124

¹²⁵*Comprehensive genomic testing in plasma*

126
127 Circulating tumor DNA was extracted from whole blood. ctDNA fragments, both leukocyte- and 128 tumor-derived, were simultaneously sequenced. The VAF was calculated as the proportion of 129 ctDNA harboring the variant in a background of wild type ctDNA. Analytical information,
130 bioinformatics analysis and Guardant360 database has been previously described [15, 16]. 130 bioinformatics analysis and Guardant360 database has been previously described [15, 16].
131

¹³²*Outcomes*

134 Assessments regarding response to therapy (complete response [CR], partial response [PR],
135 stable disease [SD], disease progression [PD]) were retrospectively collected by review of 135 stable disease [SD], disease progression [PD]) were retrospectively collected by review of
136 patient's charts. Positive response to therapy was considered PR and CR by Response 136 patient's charts. Positive response to therapy was considered PR and CR by Response
137 Evaluation Criteria in Solid Tumors (RECIST). Disease control rate was determined based on 137 Evaluation Criteria in Solid Tumors (RECIST). Disease control rate was determined based on
138 CR, PR, and SD. Progression-free survival (PFS) was determined by the time during treatment CR, PR, and SD. Progression-free survival (PFS) was determined by the time during treatment
with chemotherapy and after without disease progression. Overall survival (OS) was 139 with chemotherapy and after without disease progression.
140 determined by the time of diagnosis of advanced disease till deat 140 determined by the time of diagnosis of advanced disease till death or last day of follow up for 141 patients on treatment and alive. 141 patients on treatment and alive.
142

¹⁴³*Statistical analysis*

145 We summarized categorical data as frequency counts and percentages, and continuous
146 measures as means, standard deviations, medians, and ranges. Categorical variables were 146 measures as means, standard deviations, medians, and ranges. Categorical variables were
147 compared using the chi-square test or Fisher's exact test. Continuous variables were compared ¹⁴⁷compared using the chi-square test or Fisher's exact test. Continuous variables were compared 148 using the one-way ANOVA test or Kruskal–Wallis test. Multivariate logistic regressions were
149 performed to assess the association of ctDNA with response rate and disease control rate with 149 performed to assess the association of ctDNA with response rate and disease control rate with
150 adjustment for disease subtype, age, sex, CA19-9, lesion size, and metastatic site. The 150 adjustment for disease subtype, age, sex, CA19-9, lesion size, and metastatic site. The
151 distributions of time-to-event outcomes were estimated using the Kaplan-Meier methods and distributions of time-to-event outcomes were estimated using the Kaplan-Meier methods and 152 compared between low versus high ctDNA dichotomized by the median dominant clone allele
153 frequency (i.e., low < 3% versus high >= 3% ctDNA) using the log-rank test. Hazard ratios (HRs) 153 frequency (i.e., low < 3% versus high >= 3% ctDNA) using the log-rank test. Hazard ratios (HRs)
154 and 95% confidence intervals (CIs) were estimated using a multivariate Cox model adjusting for 154 and 95% confidence intervals (CIs) were estimated using a multivariate Cox model adjusting for
155 disease subtype, age, sex, CA19-9, lesion size, and metastatic site. Sensitivity analysis were 155 disease subtype, age, sex, CA19-9, lesion size, and metastatic site. Sensitivity analysis were
156 conducted to explore either 3-quantiles (<= 33% percentile, 34-66% percentile, > 66% 156 conducted to explore either 3-quantiles (ϵ = 33% percentile, 34-66% percentile, > 66%
157 percentile) or quartiles as the cutoffs in dominant clone allele frequency. ¹⁵⁷percentile) or quartiles as the cutoffs in dominant clone allele frequency.

- 158
159
- ¹⁵⁹**RESULTS**

160

¹⁶¹*Patient demographics*

163 A total of 67 patients were included in the analysis. 80.6% (54) had intrahepatic
164 cholangiocarcinoma, 10.4% (7) patients had extrahepatic cholangiocarcinoma and 9% (6) had ¹⁶⁴cholangiocarcinoma, 10.4% (7) patients had extrahepatic cholangiocarcinoma and 9% (6) had 165 gallbladder cancer. All patients included had ctDNA collected before the first-line chemotherapy
166 regimen for advanced disease. Median age of all patients was 67 y/o (27-90) and the majority ¹⁶⁶regimen for advanced disease. Median age of all patients was 67 y/o (27-90) and the majority 167 were female (62.6%). All patients were treated with platinum-based chemotherapy regimens as
168 first-line treatment. Most patients (68.6%) were treated with cisplatin plus gemcitabine, eleven 168 first-line treatment. Most patients (68.6%) were treated with cisplatin plus gemcitabine, eleven
169 (16,4%) patients received gemcitabine plus other platinum (carboplatin or oxaliplatin) 169 (16,4%) patients received gemcitabine plus other platinum (carboplatin or oxaliplatin)
170 combinations while ten (15%) patients were treated on a clinical trial with gemcitabine and combinations while ten (15%) patients were treated on a clinical trial with gemcitabine and 171 cisplatin plus additional agents (CX4945, PEGPH20 or nab-paclitaxel). The median size of
172 largest lesion was 6 cm (2-19cm) and more than half (58.2%) had multiple metastatic sites 172 largest lesion was 6 cm (2-19cm) and more than half (58.2%) had multiple metastatic sites
173 including liver and extrahepatic sites. Lungs, bones, lymph nodes and peritoneum were the including liver and extrahepatic sites. Lungs, bones, lymph nodes and peritoneum were the 174 sites with most extrahepatic metastasis identified. Other clinical information can be found on
175 **Table 1**. ¹⁷⁵**Table 1**.

176 Several potential targetable genes were detected with ctDNA including FGFR2, HER2, IDH,
177 MET, EGFR, BRAF and KRAS. A higher prevalence of TP53 were observed among the three 177 MET, EGFR, BRAF and KRAS. A higher prevalence of TP53 were observed among the three
178 Subtypes. Homologous recombinant repair genes were identified in IHC and EHC including ATM 178 subtypes. Homologous recombinant repair genes were identified in IHC and EHC including ATM
179 and BRCA2. Prevalence of all genomic alterations accordingly to primary tumor can be found on 179 and BRCA2. Prevalence of all genomic alterations accordingly to primary tumor can be found on
180 **Figure 1**. **Figure 1.**

181 TP53, KRAS, FGFR2, ARID1A, STK11 and IDH1 were the genes with highest variant allele
182 frequency as dominant clone (Figure 2). Most ERBB2 (HER-2) genomic alterations detected ¹⁸²frequency as dominant clone (**Figure 2**). Most ERBB2 (HER-2) genomic alterations detected 183 were amplifications, identified in 4 patients. Other genes with detected amplifications included
184 KRAS, EGFR, BRAF, MET, CCNE1, CCND1, CCND2, MYC, FGFR1, FGFR2, CDK4, CDK6, 184 KRAS, EGFR, BRAF, MET, CCNE1, CCND1, CCND2, MYC, FGFR1, FGFR2, CDK4, CDK6,
185 PIK3CA, AR. For analysis we considered the detected genomic alteration with the highest PIK3CA, AR. For analysis we considered the detected genomic alteration with the highest 186 variant allele frequency (VAF) as the dominant clone allele frequency (DCAF).

¹⁸⁸*Dominant clone allele frequency and prognostic factors*

189

190 One patient with no tumor genomic alteration detected was excluded from this analysis. The
191 median dominant clone allele frequency (DCAF) was 3% (0-97%). DCAF >3% was associated 191 median dominant clone allele frequency (DCAF) was 3% (0-97%). DCAF >3% was associated
192 with inferior PFS (median PFS: 4.7 vs. 7.7 months, p=0.087. **Supplementary figure 1**) and 192 with inferior PFS (median PFS: 4.7 vs. 7.7 months, p=0.087. **Supplementary figure 1**) and 193
193 significantly worse OS (median OS: 10.8 vs. 18.8 months, p=0.032. **Figure 3**). significantly worse OS (median OS: 10.8 vs. 18.8 months, p=0.032. Figure 3).

194 We further analyzed DCAF using either 3-quantiles or quartiles as the cutoffs. DCAF divided by
195 3 quantiles (Q1: ctDNA ≤1%, Q2: ctDNA 1-7%, Q3: ctDNA ≥7%) was significantly associated 195 3 quantiles (Q1: ctDNA ≤1%, Q2: ctDNA 1-7%, Q3: ctDNA ≥7%) was significantly associated
196 with PFS (p=0.022) (**Supplementary figure 2)** but not OS (p=0.065) (**Supplementary figure** with PFS (p=0.022) (**Supplementary figure 2)** but not OS (p=0.065) (**Supplementary figure** 197 **3**). DCAF divided by quartiles (Q1: ctDNA ≤0.6%, ctDNA Q2: 0.6-3%, ctDNA Q3: 3-10%, ctDNA
198 Q4: ≥10%) was significantly associated with PFS (p=0.014) (**Figure 4**) and OS (p=0.001) ¹⁹⁸Q4: ≥10%) was significantly associated with PFS (p=0.014) (**Figure 4**) and OS (p=0.001) ¹⁹⁹(**Figure 5**).

200 Each 1% increase in ctDNA is associated with a hazard ratio of 13.1 in OS when adjusting for
201 primary tumor, size of the largest lesion, metastatic sites, sex, age, and CA19-9 (Table 2). No 201 primary tumor, size of the largest lesion, metastatic sites, sex, age, and CA19-9 (**Table 2**). No
202 significant differences in response or disease control rate to chemotherapy was observed in 202 significant differences in response or disease control rate to chemotherapy was observed in
203 patients with low or high ctDNA (Supplementary figure 4 and 5). No statistical significance 203 patients with low or high ctDNA (**Supplementary figure 4 and 5**). No statistical significance
204 vas found between DCAF and the presence of potential actionable targets including FGFR2, 204 was found between DCAF and the presence of potential actionable targets including FGFR2,
205 IDH1/2, ERBB2 and KRAS (Supplementary figure 6). IDH1/2, ERBB2 and KRAS (Supplementary figure 6).

206 The interaction between CA19-9 and DCAF were not statistically significant (OS: P_{interaction} = $-$ 207 0.12; PFS: P_{interaction} = 0.06). Although CCA patients with high DCAF and high CA19-9 (DFCA >=

207 0.12; PFS: P_{interaction} = 0.06). Although CCA patients with high DCAF and high CA19-9 (DFCA >= 208 3%, CA19-9 >= 100) had worst OS, no statistical significance was found for PFS (p=0.19) or OS

208 3%, CA19-9 >= 100) had worst OS, no statistical significance was found for PFS (p=0.19) or OS
209 (p=0.13) (**Supplementary figures 7 and 8**).

²⁰⁹(p=0.13) (**Supplementary figures 7 and 8**).

²¹⁰**DISCUSSION**

211

212 In this study, we assessed whether the highest variant allele frequency detected by ctDNA,
213 namely DCAF, could be a prognostic factor in patients with advanced biliary tract cancer at 213 namely DCAF, could be a prognostic factor in patients with advanced biliary tract cancer at
214 diagnosis. Based on the findings, patients with DCAF>3% at diagnosis had worse overall 214 diagnosis. Based on the findings, patients with DCAF>3% at diagnosis had worse overall
215 survival when treated with upfront platinum-based chemotherapy. Furthermore, DCAF>10% 215 survival when treated with upfront platinum-based chemotherapy. Furthermore, DCAF>10%
216 vas significantly related to worse PFS and OS. However, no differences in response rate were 216 was significantly related to worse PFS and OS. However, no differences in response rate were
217 observed among patients with DCAF high or low. Moreover, ctDNA proved to be an 217 observed among patients with DCAF high or low. Moreover, ctDNA proved to be an
218 independent factor related to overall survival in multivariate analysis. Collectively, these data 218 independent factor related to overall survival in multivariate analysis. Collectively, these data
219 suggest a prognostic and not predictive role for DCAF in patients with advanced biliary tract 219 suggest a prognostic and not predictive role for DCAF in patients with advanced biliary tract
220 cancer undergoing platinum-based therapy. cancer undergoing platinum-based therapy.

221 The landscape of ctDNA genomic alterations of biliary tract cancers has already been previously
222 described [8, 17]. Similarly, to our findings, these studies included more patients with IHC, and 222 described [8, 17]. Similarly, to our findings, these studies included more patients with IHC, and
223 the genes with the highest detection with ctDNA included principally KRAS, TP53, FGFR2, IDH1 223 the genes with the highest detection with ctDNA included principally KRAS, TP53, FGFR2, IDH1
224 and ARID1A [8, 17]. In our cohort, we observed different patterns of prevalence, with ATM and 224 and ARID1A [8, 17]. In our cohort, we observed different patterns of prevalence, with ATM and
225 MAP2K1 detected in extrahepatic cholangiocarcinoma and ERBB2, NF1 and PTEN in 225 MAP2K1 detected in extrahepatic cholangiocarcinoma and ERBB2, NF1 and PTEN in
226 gallbladder cancer. gallbladder cancer.

227 Variant allele frequency is related to outcomes, it is more prominent in metastatic disease and is
228 associated with tumor volume [14, 16, 18]. In metastatic pancreatic cancer, detectable ctDNA 228 associated with tumor volume [14, 16, 18]. In metastatic pancreatic cancer, detectable ctDNA
229 and high VAF was associated with worse overall survival [18, 19, 20]. Prognostic significance 229 and high VAF was associated with worse overall survival [18, 19, 20]. Prognostic significance
230 vas observed in other solid tumors including colorectal cancer, breast cancer and prostate 230 was observed in other solid tumors including colorectal cancer, breast cancer and prostate
231 cancer [21-23]. Little is known about VAF and prognosis in biliary tract cancers. Lower values of 231 cancer [21-23]. Little is known about VAF and prognosis in biliary tract cancers. Lower values of
232 VAF were associated with prolonged progression-free survival in a cohort of 24 patients with 232 VAF were associated with prolonged progression-free survival in a cohort of 24 patients with
233 cholangiocarcinoma [18]. Considering the highest VAF value, we showed that the DCAF>3% is 233 cholangiocarcinoma [18]. Considering the highest VAF value, we showed that the DCAF>3% is
234 Frelated to numerically inferior PFS (but not statistically significant) and worse OS in patients with 234 related to numerically inferior PFS (but not statistically significant) and worse OS in patients with
235 biliary tract cancers treated with standard upfront platinum-based chemotherapy for advanced 235 biliary tract cancers treated with standard upfront platinum-based chemotherapy for advanced
236 disease. Interestingly, the DCAF was determined by multiple different genes among the cases, disease. Interestingly, the DCAF was determined by multiple different genes among the cases,

237 including TP53, KRAS, FGFR2, ARID1A, STK11 and IDH1, suggesting as previously stated by
238 other colleagues that the highest VAF would be a surrogate of disease burden not related 238 other colleagues that the highest VAF would be a surrogate of disease burden not related
239 specifically to the gene detected. In agreement with this, evaluating the presence of specific 239 specifically to the gene detected. In agreement with this, evaluating the presence of specific
240 genes of interest in the ctDNA overall analysis we did not found any association with DCAF and 240 genes of interest in the ctDNA overall analysis we did not found any association with DCAF and
241 possible targetable genes including FGFR2, ERBB2, IDH1 and KRAS. possible targetable genes including FGFR2, ERBB2, IDH1 and KRAS.

242 Prognostic factors related to PFS and OS in advanced biliary tract cancers were evaluated from
243 the ABC-02 trial and an international dataset [24]. In this analysis, the authors evaluated 243 the ABC-02 trial and an international dataset [24]. In this analysis, the authors evaluated
244 Prognostic factors in a combined sample size of more than one thousand patients [24]. Although 244 prognostic factors in a combined sample size of more than one thousand patients [24]. Although
245 bthe results suggest multiples factors in multivariate analysis including hemoglobin, gender and 245 the results suggest multiples factors in multivariate analysis including hemoglobin, gender and
246 neutrophils, receiver operator curve (ROC) analysis suggested that the model generated had a ²⁴⁶neutrophils, receiver operator curve (ROC) analysis suggested that the model generated had a 247 limited prognostic value [24]. Even the primary tumor site was not significant, in contrast to the 248 findings of other groups [25]. After multiple efforts evaluating scores and factors to 248 findings of other groups [25]. After multiple efforts evaluating scores and factors to
249 prognostication of advanced biliary tract cancers [26, 27, 28], the ability to predict prognosis 249 prognostication of advanced biliary tract cancers [26, 27, 28], the ability to predict prognosis
250 need improvement. In our analysis, the overall survival impact of ctDNA was observed after 250 need improvement. In our analysis, the overall survival impact of ctDNA was observed after
251 stratifving with other possible prognostic factors including size of largest lesion. locally 251 stratifying with other possible prognostic factors including size of largest lesion, locally
252 advanced/metastatic designation, primary tumor location, metastatic sites, gender, CA 19-9 and 252 advanced/metastatic designation, primary tumor location, metastatic sites, gender, CA 19-9 and
253 age. Evaluating ctDNA as a continuous variable, higher values are related to inferior survival 253 age. Evaluating ctDNA as a continuous variable, higher values are related to inferior survival
254 probabilities. Based on the findings, ctDNA and DCAF could be a reliable easy to collect 254 probabilities. Based on the findings, ctDNA and DCAF could be a reliable easy to collect 255 prognostic instrument in prospective trials. prognostic instrument in prospective trials.

256 Considering the investigative field of ctDNA in biliary tract cancers, larger, multi-centered
257 prospective studies would be necessary to address the application of ctDNA in the multiple 257 prospective studies would be necessary to address the application of ctDNA in the multiple
258 disease assessment junctures, considering early diagnosis, minimal residual disease 258 disease assessment junctures, considering early diagnosis, minimal residual disease
259 assessment, monitoring in advanced stages during systemic treatment and assessment of 259 assessment, monitoring in advanced stages during systemic treatment and assessment of
260 mutations that associate with resistance during treatment with targeted therapies. Evaluation of 260 mutations that associate with resistance during treatment with targeted therapies. Evaluation of
261 ctDNA and DCAF in metastatic disease would be a tool for genomic profiling in prospective 261 ctDNA and DCAF in metastatic disease would be a tool for genomic profiling in prospective
262 trials, can be a surrogate of disease volume and will assist in an adequate stratification of 262 trials, can be a surrogate of disease volume and will assist in an adequate stratification of
263 patients with advanced biliary tract cancer in randomized studies. patients with advanced biliary tract cancer in randomized studies.

264 Some limitations of this study include the number of patients, limited institution aspect, inherent
265 limitations associated with a targeted gene panel and the retrospective nature of data collection. 265 limitations associated with a targeted gene panel and the retrospective nature of data collection.
266 Furthermore, most of the patients included had tumor arising from the intrahepatic duct. This 266 Furthermore, most of the patients included had tumor arising from the intrahepatic duct. This
267 Iimitation is shared with studies in biliary tract cancers and efforts should be made to include limitation is shared with studies in biliary tract cancers and efforts should be made to include 268 patients with extrahepatic and gallbladder carcinomas in initiatives of genomic profiling and

269 ctDNA. Even with the limited number of patients, strong association of ctDNA and OS were
270 observed. This study only evaluated patients treated with upfront chemotherapy. Although this is

270 observed. This study only evaluated patients treated with upfront chemotherapy. Although this is
271 the standard of care to date, multiple trials are evaluating targeted treatments including FGFR2

271 the standard of care to date, multiple trials are evaluating targeted treatments including FGFR2
272 inhibitors in the first-line therapy for advanced disease and it would be unclear if upfront tyrosine

272 inhibitors in the first-line therapy for advanced disease and it would be unclear if upfront tyrosine
273 binase inhibitors would alter the results. On the other hand, as stated before, the presence of

273 kinase inhibitors would alter the results. On the other hand, as stated before, the presence of 274 targetable genes had no association with DCAF results and impact of ctDNA on overall survival. targetable genes had no association with DCAF results and impact of ctDNA on overall survival.

²⁷⁵**CONCLUSION**

276 ctDNA is a powerful prognostic tool in advanced biliary tract cancers. DCAF at diagnosis of
277 advanced disease who would receive platinum based systemic therapy identifies patients with 277 advanced disease who would receive platinum based systemic therapy identifies patients with
278 vorse prognosis. ctDNA should be evaluated in prospective trials as a stratification factor for 278 worse prognosis. ctDNA should be evaluated in prospective trials as a stratification factor for 279 advanced disease. advanced disease.

280

²⁸¹**REFERENCES**

- 282 1. de Groen, P.C., et al., Biliary tract cancers. N Engl J Med, 1999. 341(18): p. 1368-78.
283 28. Charbel, H. and F.H. Al-Kawas, Cholangiocarcinoma: epidemiology, risk facto
- 283 2. Charbel, H. and F.H. Al-Kawas, Cholangiocarcinoma: epidemiology, risk factors,
284 pathogenesis, and diagnosis. Curr Gastroenterol Rep, 2011. 13(2): p. 182-7. pathogenesis, and diagnosis. Curr Gastroenterol Rep, 2011. 13(2): p. 182-7.
285 3. Siegel, R.L., et al., Cancer Statistics, 2021. CA: A Cancer Journal for Clinic
- 285 3. Siegel, R.L., et al., Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 2021.
286 71(1): p. 7-33. 286 71(1): p. 7-33.
287 4. Shroff, R.T., e
- 287 4. Shroff, R.T., et al., Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical
288 Practice Guideline. J Clin Oncol, 2019. 37(12): p. 1015-1027. 288 Practice Guideline. J Clin Oncol, 2019. 37(12): p. 1015-1027.
289 5. Farley, D.R., A.L. Weaver, and D.M. Nagorney, "Natura
- 289 5. Farley, D.R., A.L. Weaver, and D.M. Nagorney, "Natural history" of unresected
290 cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc, 290 cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc,
291 1995. 70(5): p. 425-9.
- 291 1995. 70(5): p. 425-9.
292 6. Valle, J., et al., Cispla ²⁹²6. Valle, J., et al., Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N 293 Engl J Med, 2010. 362(14): p. 1273-81.
294 7. Valle, J.W., et al., New Horizons for Pre
- 294 7. Valle, J.W., et al., New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer
295 Discov, 2017. 7(9): p. 943-962. 295 Discov, 2017. 7(9): p. 943-962.
296 8. Mody, K., et al., Circulating To
- ²⁹⁶8. Mody, K., et al., Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. 297 JCO Precision Oncology, 2019(3): p. 1-9.
298 9. Lu, L., J. Bi, and L. Bao, Genetic profiling
- 298 9. Lu, L., J. Bi, and L. Bao, Genetic profiling of cancer with circulating tumor DNA analysis.
299 J Genet Genomics, 2018. 45(2): p. 79-85. J Genet Genomics, 2018. 45(2): p. 79-85.

300 10. Hovelson, D.H., et al., Rapid, ultra low coverage copy number profiling of cell-free DNA
301 as a precision oncology screening strategy. Oncotarget, 2017. 8(52): p. 89848-89866. 301 as a precision oncology screening strategy. Oncotarget, 2017. 8(52): p. 89848-89866.
302 11. Goval. L., et al., Polyclonal Secondary FGFR2 Mutations Drive Acquir

- 302 11. Goyal, L., et al., Polyclonal Secondary FGFR2 Mutations Drive Acquired
303 Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive 303 Resistance to FGFR Inhibition in Patients with FGFR2
304 Cholangiocarcinoma.CancerDiscovery, 2017. 7(3): p. 252-263.
- 304 Cholangiocarcinoma. Cancer Discovery, 2017. 7(3): p. 252-263.
305 12. Reece, M., et al., The Use of Circulating Tumor DNA to Monitor 305 12. Reece, M., et al., The Use of Circulating Tumor DNA to Monitor and Predict Response to
306 Treatment in Colorectal Cancer. Frontiers in genetics, 2019. 10: p. 1118-1118. 306 Treatment in Colorectal Cancer. Frontiers in genetics, 2019. 10: p. 1118-1118.
307 13. Li. S., et al., Circulating Tumor DNA Predicts the Response and Prognosis in
- 13. Li, S., et al., Circulating Tumor DNA Predicts the Response and Prognosis in Patients
308 With Early Breast Cancer Receiving Neoadjuvant Chemotherapy. JCO Precision ³⁰⁸With Early Breast Cancer Receiving Neoadjuvant Chemotherapy. JCO Precision 309 Oncology, 2020(4): p. 244-257.
310 14. Pairawan, S., et al., Cell-fre
- 310 14. Pairawan, S., et al., Cell-free Circulating Tumor DNA Variant Allele Frequency
311 68 Associates with Survival in Metastatic Cancer. Clin Cancer Res, 2020. 26(8): p. 1924-311 Associates with Survival in Metastatic Cancer. Clin Cancer Res, 2020. 26(8): p. 1924-
312 1931. 1931.
- 313 15. Lanman, Richard B., et al. "Analytical and clinical validation of a digital sequencing panel
314 15. The quantitative. highly accurate evaluation of cell-free circulating tumor DNA." PloS 314 for quantitative, highly accurate evaluation of cell-free circulating tumor DNA." *PloS* 315 *one* 10.10 (2015): e0140712. ³¹⁵*one* 10.10 (2015): e0140712.
- 316 16. Botrus, Gehan, et al. "Circulating Tumor DNA-Based Testing and Actionable Findings in
317 12 Patients with Advanced and Metastatic Pancreatic Adenocarcinoma." The
318 0ncologist (2021). ³¹⁷Patients with Advanced and Metastatic Pancreatic Adenocarcinoma." *The* ³¹⁸*Oncologist* (2021).
- 319 17. Okamura, Ryosuke, et al. "Comprehensive genomic landscape and precision therapeutic
320 **produce approach in biliary tract cancers**." *International journal of cancer* 148.3 (2021): 702-712. ³²⁰approach in biliary tract cancers." *International journal of cancer* 148.3 (2021): 702-712.
- 18. Strijker, Marin, et al. "Circulating tumor DNA quantity is related to tumor volume and both
322 predict survival in metastatic pancreatic ductal adenocarcinoma." *International journal of* 322 predict survival in metastatic pancreatic ductal adenocarcinoma." *International journal of 323* cancer 146.5 (2020): 1445-1456. ³²³*cancer* 146.5 (2020): 1445-1456.
- 19. Bernard, Vincent, et al. "Circulating nucleic acids are associated with outcomes of
325 http://east.cancer." Gastroenterology 156.1 (2019): 108-118. ³²⁵patients with pancreatic cancer." *Gastroenterology* 156.1 (2019): 108-118.
- 326 20. Patel, Hitendra, et al. "Clinical correlates of blood-derived circulating tumor DNA in
327 pancreatic cancer." Journal of hematology & oncology 12.1 (2019): 1-12. ³²⁷pancreatic cancer." *Journal of hematology & oncology* 12.1 (2019): 1-12.

21. Dasari, Arvind, et al. "ctDNA applications and integration in colorectal cancer: An NCI
329 Colon and Rectal–Anal Task Forces whitepaper." Nature Reviews Clinical ³²⁹Colon and Rectal–Anal Task Forces whitepaper." *Nature Reviews Clinical* ³³⁰*Oncology* 17.12 (2020): 757-770.

- 22. Cullinane, Carolyn, et al. "Association of Circulating Tumor DNA With Disease-Free
332 Survival in Breast Cancer: A Systematic Review and Meta-analysis." JAMA network 332 Survival in Breast Cancer: A Systematic Review and Meta-analysis." *JAMA network* **and it and it and it also it and it a** ³³³*open* 3.11 (2020): e2026921-e2026921.
- 23. Goodall, Jane, et al. "Circulating tumor DNA (ctDNA) dynamics associate with treatment
335 response and radiological progression-free survival (rPFS): Analyses from a randomized response and radiological progression-free survival (rPFS): Analyses from a randomized 336 bhase II trial in metastatic castration-resistant prostate cancer (mCRPC)." JCO (2020):
337 5508-5508. ³³⁷5508-5508.
- ³³⁸24. Bridgewater, John, et al. "Prognostic factors for progression-free and overall survival in ³³⁹advanced biliary tract cancer." *Annals of Oncology* 27.1 (2016): 134-140.
- 340 25. Peixoto RDA, Renouf D, Lim H. A population based analysis of prognostic factors in
341 **2014; 1998** advanced biliary tract cancer. J Gastrointest Oncol 2014; 5: 428–432. advanced biliary tract cancer. J Gastrointest Oncol 2014; 5: 428–432.
- 26. Park, Hyung Soon, et al. "Prognostic factors and scoring model for survival in metastatic
343 biliary tract cancer." Cancer research and treatment: official journal of Korean Cancer 343 biliary tract cancer." *Cancer research and treatment: official journal of Korean Cancer 344* **Association 49.4 (2017): 1127.** ³⁴⁴*Association* 49.4 (2017): 1127.
- 27. Salati, Massimiliano, et al. "The prognostic nutritional index predicts survival and
346 response to first-line chemotherapy in advanced biliary cancer." *Liver International* 40.3 346 response to first‐line chemotherapy in advanced biliary cancer." *Liver International* 40.3 ³⁴⁷(2020): 704-711.
- 28. Kim, Bum Jun, et al. "Prognostic factors in patients with advanced biliary tract cancer
349 treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 349 treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740
350 patients." Cancer chemotherapy and pharmacology 80.1 (2017): 209-215. patients." Cancer chemotherapy and pharmacology 80.1 (2017): 209-215.
-
-
- 353
-

 Tables and figures Table 1: Demographic characteristics Table 2: Multivariate analysis for overall survival Figure 1: Prevalence of genomic alterations accordingly to primary tumor Figure 2: Variant allele frequency of detected genes Figure 3: Overall survival Kaplan-Meier curve by DCAF>3% Figure 4: Progression-free survival Kaplan-Meier curve by ctDNA Figure 5: Overall survival Kaplan-Meier curve by ctDNA Supplementary figure 1: Progression-free survival and DCAF>3% Supplementary figure 2: Progression-free survival and DCAF quartiles Supplementary figure 3: Overall survival and DCAF quartiles Supplementary figure 4: ctDNA Response vs. Non−Response. p = 0.2678 Supplementary figure 5: ctDNA Disease Control vs. Disease progression. p = 0.0843 Supplementary figure 6: ctDNA by Group. p = 0.1373 Supplementary figure 7: CA19-9 and DCAF impact on PFS Supplementary figure 8: CA19-9 and DCAF impact on OS

-
-
- 399 400
-
- 401
- 402
- 403
- 404

⁴⁰⁵**Table 2: Multivariate analysis for overall survival**

406

407

- 411
- 412
- 413
-
- 414
- 415
- 416
-
- 417
- 418

-
-
-
-
-

Figure 2: Variant allele frequency of detected genes

-
-
-
-
-
-
-
-
-

-
-

Figure 3: Overall survival Kaplan-Meier curve by DCAF>3%

-
-
-

-
-
-
-
-
-
-

488

490 **Figure 5: Overall survival Kaplan-Meier curve by groups**

491

medRxiv preprint doi: https://doi.org/10.1101/2021.11.01.21265773; this version posted November 2, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/tunder, who has granted The copyright holder for this preprint is exailed November 2, 2021. [;](https://doi.org/10.1101/2021.11.01.21265773) 10.121.101.21.11.101.21. ; https://doi.11101/2021.11.01.21267.21. ; https://doi.2126773 doi: medRxiv preprint is preprint is preprint is exailed to 2021 who has granted by perfact in the authorycle and has granted medRxix a license to display the prepriation in perpetuity. . [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) It is made available under a